• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca sells Alderley Park site in Cheshire, U.K.

AstraZeneca sells Alderley Park site in Cheshire, U.K.

March 12, 2014
CenterWatch Staff

AstraZeneca has sold its Alderley Park site in Cheshire, U.K., to Manchester Science Parks(MSP), a Greater Manchester-based public-private partnership and science park operator.

The sale is part of AZ’s plan to establish a new global R&D center and corporate headquarters in Cambridge, U.K., in 2016. The new owners plan to build on Alderley Park’s heritage of scientific innovation, ensuring that the 400-acre site remains a life science and biotechnology campus. The financial terms of the transaction have not been disclosed.

Pascal Soriot, CEO, AstraZeneca, said, “The sale of the site to Manchester Science Parks is the responsible and sustainable choice for the future of Alderley Park. The new owner is committed to building on AstraZeneca’s life science legacy at the site and ensuring it remains a center of biotechnology innovation in the North West of England. It will lead to future growth and offer significant opportunities for new jobs to be created.”

Chris Oglesby, chairman of MSP and chief executive of MSP majority shareholder Bruntwood, said, “We are committed to developing a bioscience business cluster of international importance on the site, making it a flagship location of its kind for the North of England and the U.K.”

AZ will take pre-tax impairment charges of $275 million to non-core R&D expense in the first quarter of 2014. AZ expects to complete the sale by the end of March and will remain a key tenant on the site. The handover of the site will be phased over a three-year period, with the full exit of AZ’s R&D staff to take place when its new facility is completed. 

Alderley Park will remain a major location for AZ in the U.K., with about 700 staff on the site in non-R&D roles following the transition to Cambridge. Overall, AZ will continue to have a significant presence in the North West of England with approximately 3,000 employees across Alderley Park, the Macclesfield manufacturing site and the MedImmune vaccine manufacturing facility in Speke. The company also has extensive and close scientific collaborations with academic institutions such as Manchester University, which will continue to play an important role in discovery work.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing